ReviewMediterranean journal of rheumatology2020
Kawasaki Disease and COVID-19.
Review in Mediterranean journal of rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Oral manifestations of COVID-19 and its management in pediatric patients: A systematic review and practical guideline.Clinical and experimental dental research · 2023Pooled it
- One-Year Follow-Up Results of MIS-C Patients with Coronary Artery Involvement: A Multi-center Study.Pediatric cardiology · 2024Article
- Clinical and Laboratory Characteristics of Kawasaki Disease and COVID-19-Related Multisystem Inflammatory Syndrome in Children.Journal of Korean medical science · 2023Article
- Concomitant Kawasaki Disease and Rotavirus Infection-More Than Just a Coincidence: A Case Report.Tropical medicine and infectious disease · 2023Article
- Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) in a Middle Eastern patient cohort.Pediatric rheumatology online journal · 2023Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- SARS-CoV-2 infection in the context of Kawasaki disease and multisystem inflammatory syndrome in children.Medical microbiology and immunology · 2023Review
- Research trends on causes of Kawasaki disease in the COVID-19 era: focus on viral infections.Clinical and experimental pediatrics · 2023Article
- Ultrasound evaluation of endothelial dysfunction in immunoglobulin-resistant children with acute Kawasaki disease.Clinical rheumatology · 2022Article
- SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era.Virology journal · 2022Review
- Case of adult-onset Kawasaki disease and multisystem inflammatory syndrome following SARS-CoV-2 vaccination.BMJ case reports · 2022Article
- COVID-19 associated vasculitis: A systematic review of case reports and case series.Annals of medicine and surgery (2012) · 2022Review
- COVID-19 Pediatric Dermatology.Dermatologic clinics · 2021Review
- Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19.Diagnostics (Basel, Switzerland) · 2021Review
- Emerging importance of ACE2 in external stratified epithelial tissues.Molecular and cellular endocrinology · 2021Review
- Coronary Vasculitis.Biomedicines · 2021Review
- Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity.Journal of clinical medicine · 2021Review
- Review
- A 14-Year-Old Male Patient with Kawasaki Disease Presented with Stroke after COVID-19.Case reports in infectious diseases · 2021Article
- Case Report: Changes in Cytokine Kinetics During the Course of Disease in a Japanese Patient With Multisystem Inflammatory Syndrome in Children.Frontiers in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent passing away of Dr. Tomisaku Kawasaki, who first described what is now known as Kawasaki Disease (KD), and recent reports of a multisystem inflammatory disease in children associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (MIS-C), makes a review on KD and MIS-C timely. Kawasaki Disease is a systemic vasculitis with predilection for coronary arteries occurring mostly in early childhood. The main features are high fever, extensive skin rash, cheilitis with red, cracking, bleeding lips and strawberry tongue, conjunctivitis, erythema and induration of hands and feet, subsiding with periungual peeling, cervical lymphadenopathy, and coronary artery dilation/aneurysms. Treatment consists of intravenous (IV) immunoglobulin (Ig) plus acetylsalicylic acid. MIS-C is considered a cytokine storm with high fever, inflammation, multi-organ dysfunction, that shares features with KD, toxic shock, and macrophage activation syndrome. Many children require admission to paediatric intensive care units for circulatory support. Bacterial sepsis, staphylococcal toxic shock syndrome, and enterovirus-causing myocarditis should be excluded. Treatment is not standardized and includes IVIg, IV methylprednisolone and IL-6 and IL-1 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.